Shire's angioedema drug succeeds in late-stage study

Shire's angioedema drug succeeds in late-stage study

REUTERS: Shire Plc said on Thursday its drug for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling, was successful in a late-stage study.

The drug, lanadelumab, is being developed to prevent angioedema attacks. It was tested against a placebo over 26 weeks in patients 12 years of age or older with the rare genetic disease.

(Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)

Source: Reuters